ADARx Pharmaceuticals (NASDAQ:ADRX - Get Free Report) had its target price dropped by analysts at JPMorgan Chase & Co. from $38.00 to $36.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price target would suggest a potential upside of 163.54% from the company's current price.
Several other research analysts also recently commented on ADRX. Wall Street Zen raised shares of ADARx Pharmaceuticals to a "hold" rating in a research note on Saturday, October 3rd. Zacks Research raised shares of ADARx Pharmaceuticals to a "hold" rating in a research note on Wednesday, October 21st. Morgan Stanley began coverage on shares of ADARx Pharmaceuticals in a report on Tuesday, October 20th. They set an "overweight" rating and a $32.00 target price on the stock. UBS Group assumed coverage on shares of ADARx Pharmaceuticals in a research report on Tuesday, October 20th. They issued a "buy" rating and a $35.00 target price on the stock. Finally, TD Cowen started coverage on shares of ADARx Pharmaceuticals in a research note on Tuesday, October 20th. They issued a "buy" rating for the company. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $34.33.
Read Our Latest Research Report on ADARx Pharmaceuticals
ADARx Pharmaceuticals Stock Up 6.6%
ADRX stock traded up $0.84 during mid-day trading on Thursday, hitting $13.66. 282,301 shares of the stock were exchanged, compared to its average volume of 550,605. ADARx Pharmaceuticals has a 12 month low of $12.50 and a 12 month high of $23.21.
ADARx Pharmaceuticals (NASDAQ:ADRX - Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($1.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by ($1.34). On average, sell-side analysts forecast that ADARx Pharmaceuticals will post -2.03 EPS for the current year.
Insider Activity
In other news, Director Erez Chimovits bought 61,516 shares of the business's stock in a transaction dated Monday, September 28th. The shares were purchased at an average price of $17.00 per share, for a total transaction of $1,045,772.00. Following the completion of the acquisition, the director owned 9,292,025 shares of the company's stock, valued at approximately $157,964,425. This trade represents a 0.67% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Simeon George purchased 1,600,000 shares of the stock in a transaction that occurred on Monday, September 28th. The shares were purchased at an average price of $17.00 per share, with a total value of $27,200,000.00. Following the completion of the acquisition, the director directly owned 5,554,094 shares in the company, valued at $94,419,598. The trade was a 40.46% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders purchased 3,261,516 shares of company stock valued at $55,445,772.
Hedge Funds Weigh In On ADARx Pharmaceuticals
A hedge fund recently bought a new stake in ADARx Pharmaceuticals stock. Readystate Asset Management LP bought a new position in ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 25,000 shares of the company's stock, valued at approximately $498,000.
About ADARx Pharmaceuticals
(
Get Free Report)
ADARx Pharmaceuticals is a clinical-stage biopharmaceutical company developing RNA-targeted medicines for serious diseases. Its research focuses on oligonucleotide therapeutics designed to alter the activity of specific RNA molecules and, in turn, address disease-related gene expression. The company's pipeline includes investigational candidates for conditions such as hereditary angioedema and complement-mediated diseases. These therapies remain in development and have not been established as approved treatments.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ADARx Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADARx Pharmaceuticals wasn't on the list.
While ADARx Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.